All articles by Rosanna Jeffery
Rosanna Jeffery
M&As this week: Hildred Capital Partners, Novartis, Neos Therapeutics
Private investment firm Hildred Capital Partners plans to acquire a majority stake in pharmaceutical company Crown Laboratories.
Deals this week: Xiangxue Pharmaceutical, Sumitomo Dainippon Pharma, Zhongzhi Pharmaceutical Holdings
Chinese pharmaceutical products manufacturer Xiangxue Pharmaceutical has raised CNY600m ($90.23m) through a public offering of corporate bonds.
Report: Indonesian pharmaceutical market to be worth $10.11bn by 2021
Indonesia’s pharmaceutical market is projected to reach $10.11bn by 2021, according to a report by GlobalData.
M&As this week: WuXi AppTec, Cachet Pharmaceutical, Shenzhen Neptunus Bioengineering
Chinese pharmaceutical company WuXi AppTec plans to acquire US-based contract research organisation (CRO) ResearchPoint Global (RPG).
Deals this week: Harbin Gloria Pharmaceuticals, F. Hoffmann-La Roche, Intrexon
Chinese pharmaceutical company Harbin Gloria Pharmaceuticals intends to issue medium-term notes due 2019 in a public offering to raise CNY1.6bn ($243.13m).
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Report: Alzheimer’s market set to achieve double-digit growth by 2026
The global Alzheimer’s disease (AD) market is expected to increase from $2.9bn in 2016 to $14.8bn, rising at a compound annual growth rate (CAGR) of 17.5%, according to a report by GlobalData.
Deals this week: Catalent Pharma Solutions, China Grand Pharmaceutical and Healthcare Holdings, Recursion Pharmaceuticals
US-based pharmaceutical company Catalent Pharma Solutions plans to raise $450m through the private placement of senior unsecured notes, due 2026.
M&As this week: First Coin Capital, China Grand Pharmaceutical and Healthcare Holdings, Tael Management
US-based pharmaceutical company Catalent Pharma Solutions plans to raise $450m through the private placement of senior unsecured notes, due 2026.
FDA grants breakthrough status to new Hodgkin’s lymphoma therapy
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Adcetris (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin’s lymphoma.
Transgene and Randox to develop oncolytic treatment for solid tumours
Transgene has a partnered with in-vitro diagnostics company Randox to combine their technologies and develop multifunctional oncolytic immunotherapies.